Meet us at Bio Europe 2026 in Cologne, Germany

Join us at BIO Europe 2026 in Cologne, Germany from November 9th to 11th, and meet our Managing Director, Stijn Otte. Sillar Clinical has a proven track record of guiding and supporting SME Medtech and Biotech companies as well as academic institutions. We specialize in the setup and conduct of your clinical trials, as well as helping you smoothly transition from pre-clinical to clinical. 

About Bio Europe 2026:

BIO-Europe: Where partnerships help shape the future of biopharma

Developing a new therapy requires more than promising science. It takes funding, expertise and collaboration between organisations with complementary capabilities. BIO-Europe brings these stakeholders together, creating opportunities to connect scientific innovation with the resources needed to advance it.

The event gathers biotechnology and pharmaceutical companies, investors and specialist partners from across the international life sciences community. Its focus extends from identifying promising technologies to discussing the strategic decisions that influence their development.

Partnerships at the heart of drug development

Partnering is a central feature of BIO-Europe. Discussions can open the door to licensing agreements, investment, research collaborations and development partnerships. For emerging biotech companies, these exchanges offer opportunities to introduce their programmes and explore potential support. For pharmaceutical companies, they provide a setting to identify external innovation that could complement their pipelines.

The value of these conversations goes beyond an immediate agreement. Understanding a potential partner’s scientific priorities, development approach and expectations can help establish the foundations for a longer-term relationship.

A broader perspective on the biopharma industry

BIO-Europe’s 2026 programme expands its focus across regulatory affairs, clinical development, manufacturing, investment and commercialisation. This broader agenda reflects how closely these areas are connected: decisions made early in development can influence subsequent clinical, operational and commercial pathways.

The programme also addresses questions shaping the sector’s future, including the changing investment environment, lessons from recent biotech deals and opportunities in underserved areas such as women’s health. These discussions connect individual development programmes with wider industry challenges and unmet needs.

Connecting innovation with clinical development expertise

For companies moving towards clinical development, a promising asset brings a new set of questions. How can the development strategy translate into a feasible study? What expertise and resources will be needed? How can scientific ambitions align with operational realities?

BIO-Europe provides a setting for biotech companies and clinical development partners to explore these questions together. Early dialogue can help clarify priorities, identify potential challenges and assess where complementary expertise could support a programme’s next milestones.

For CROs, these exchanges also offer a deeper understanding of the organisations behind the science, their ambitions, constraints and expectations of a clinical partner.

Building relationships that support progress

The significance of BIO-Europe lies in the connections it makes possible across the biopharma ecosystem. Bringing scientific, financial and development perspectives into the same conversation can help organisations identify common goals and assess how they might work together.

For an industry built on complex development journeys, these relationships can play an important role in helping promising research progress towards meaningful outcomes for patients.

For more information about the event, click here

You can book your meeting with Sillar Clinical's team through the contact page of our website and through the event's platform.

We are looking forward to meeting you during Bio Europe 2026 in Cologne!